StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$15.25−0.85 (-5.28%)

Close on Nov 20, 2026Market cap $2.82BP/E –Yield –

Legend Biotech free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Legend Biotech's free cash flow for the twelve months ending Jun 30, 2026 was -$121.80M. For fiscal 2025 it was -$128.80M. The highest annual figure on record is $286.72M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$128.80M–
FY2024Dec 31, 2024-$158.10M–
FY2023Dec 31, 2023-$413.40M–
FY2022Dec 31, 2022-$222.21M–
FY2021Dec 31, 2021-$240.66M–
FY2020Dec 31, 2020-$249.26M–
FY2019Dec 31, 2019-$109.84M-138.3%
FY2018Dec 31, 2018$286.72M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$28.40M–
Q1 FY2026Mar 31, 2026-$92.60M–
Q4 FY2025Dec 31, 2025-$24.57M–
Q3 FY2025Sep 30, 2025$23.77M–
Q2 FY2025Jun 30, 2025-$22.40M–
Q1 FY2025Mar 31, 2025-$105.60M-1238.5%
Q4 FY2024Dec 31, 2024-$84.42M–
Q3 FY2024Sep 30, 2024-$77.89M–
Q2 FY2024Jun 30, 2024-$5.07M–
Q1 FY2024Mar 31, 2024$9.28M–
Q4 FY2023Dec 31, 2023-$100.03M–
Q3 FY2023Sep 30, 2023-$66.23M–
Q2 FY2023Jun 30, 2023-$103.66M–
Q1 FY2023Mar 31, 2023-$143.49M–
Q4 FY2022Dec 31, 2022-$56.30M–
Q3 FY2022Sep 30, 2022-$74.69M–

More Legend Biotech figures

See a number that looks wrong?